PedAM
Pediatric Disease Annotations & Medicines
| Disease | prostate cancer |
| Symptom | |bone metastases |
| Sentences | 122 |
| PubMedID- 22477263 | We aimed to assess the effect of sr-89 radionuclide therapy on quality of life (qol) in prostate cancer patients with painful bone metastases. |
| PubMedID- 25243101 | Methods: the us food and drug administration recently approved radium-223 (ra-223) dichloride (ra-223; xofigo injection) alpha-particle therapy for the treatment of symptomatic bone metastases in patients with castration-resistant prostate cancer. |
| PubMedID- 23947784 | Bone scan is the most common method for monitoring bone metastases in patients with advanced prostate cancer, e.g. |
| PubMedID- 22523198 | Background: secondary hyperparathyroidism is frequent in prostate cancer patients with bone metastases, and this condition is worsened by the administration of potent bisphosphonates. |
| PubMedID- 26222216 | An analysis is presented of the possible dosimetric consequences of various potential contamination events involving 223ra dichloride (xofigo), the fda-approved therapeutic agent used in the treatment of bone metastases in patients with castration-resistant prostate cancer. |
| PubMedID- 25471685 | Methods: all chinese prostate cancer patients with bone metastases who were treated with primary adt from 2000 to 2009 were included. |
| PubMedID- 24841276 | Comparison of choline-pet/ct, mri, spect, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. |
| PubMedID- 22258372 | The standard care in prostate cancer patients with bone metastases to prevent skeletal-related events (sre) are bisphosphonates. |
| PubMedID- 23710201 | Increased levels of activin a have been described in the bone marrow plasma of breast and prostate cancer with bone metastases . |
| PubMedID- 25012268 | Background: a bone scan is a common method for monitoring bone metastases in patients with advanced prostate cancer. |
| PubMedID- 25688243 | prostate cancer patients with bone metastases had higher ccl2 serum levels than patients with localized tumors (155). |
| PubMedID- 23349921 | Radium-223 chloride has been granted fast track designation by the u.s. food and drug administration for the treatment of hormone-refractory prostate cancer in patients with bone metastases . |
| PubMedID- 23858298 | Decreased levels of a2mg have been found in prostate cancer patients with bone metastases (where it is inversely related to prostate-specific antigen, psa, levels) and its measurement has been suggested for diagnosis and follow-up in these patients. |
| PubMedID- 20661742 | Whole-body mri (wb-mri) versus axial skeleton mri (as-mri) to detect and measure bone metastases in prostate cancer (pca). |
| PubMedID- 22966907 | Background: bone loss and pathological fractures are common skeletal complications associated with androgen deprivation therapy and bone metastases in prostate cancer patients. |
| PubMedID- 25406200 | We present a case of an 84-year-old belgian man, presenting prostate cancer with bone metastases. |
| PubMedID- 21309480 | Further clinical studies involving breast and prostate cancer patients with bone metastases are warranted to confirm these findings. |
| PubMedID- 23614058 | For example, the life expectancy of korean prostate cancer patients with multiple bone metastases is not yet known. |
| PubMedID- 22991663 | On the basis of this result, we grouped our prostate cancer patients with bone metastases likewise and applied radiotherapy to metastatic bone disease in eod i cases (i.e., oligometastases and oligo-recurrence of bone in prostate cancer) regardless of the presence of the bone pain. |
| PubMedID- 25234025 | Prognostic significance of time to prostate-specific antigen (psa) nadir and its relationship to survival beyond time to psa nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy. |
| PubMedID- 22307372 | Bisphosphonates: prevention of bone metastases in prostate cancer. |
| PubMedID- 23053328 | In recent years several clinical trials have been carried out showing, in particular, the safety and efficacy of palliation of painful bone metastases in patients with castration-resistant prostate cancer using (223)ra-chloride. |
| PubMedID- 21936956 | Investigated in a study in 117 prostate cancer patients with bone metastases receiving zoledronic acid the predictive effect of a range of bone turnover markers, they created cox regression models with clinical factors and bone markers and eventually showed the baseline ntx level as predictor of sres (hr, 3.33; 95%ci, 1.66-6.72, p = 0.0007) . |
| PubMedID- 26532489 | Radio-223 in the treatment of metastatic castration resistant prostate cancer with bone metastases: budget impact analysis of the national health service. |
| PubMedID- 21353695 | Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. |
| PubMedID- 21469915 | Objective: zoledronic acid (zol) reduces the risk of skeletal related events (sres) in hormone-refractory prostate cancer (hrpc) patients with bone metastases. |
| PubMedID- 23976864 | In summarizing their findings, sartor et al assert that 153sm-edtmp is an effective and safe tool for managing painful bone metastases in patients with hormone-refractory prostate cancer. |
| PubMedID- 22500564 | In a recent interim analysis of a phase iii clinical study, a novel bone-modulating agent - radium-223 chloride (alpharadin), a bone-seeking alpha emitter, has been demonstrated to significantly improve median overall survival of prostate cancer patients with bone metastases compared with placebo. |
| PubMedID- 23337762 | Effective management of bone metastases in men with castration-resistant prostate cancer (crpc) remains an important unmet medical need. |
| PubMedID- 24418365 | Introduction: procollagen 1 amino-terminal propeptide (p1np) is a bone formation marker and has been shown to have a strong association with the extent of bone metastases (bm) in patients with advanced prostate cancer. |
| PubMedID- 22710580 | Purpose of review: bone metastases in prostate cancer are often the cause of significant morbidity in patients with castrate-resistant disease, and several studies have shown significant pain palliation with systemic radionuclide treatment. |
| PubMedID- 24080992 | Currently, zoledronic acid is used only to prevent skeletal-related events related to castration-resistant prostate cancer in men with bone metastases. |
| PubMedID- 23049248 | Having shown significant clinical advantages over zoledronic acid, denosumab has gained rapid adoption by physicians treating prostate cancer patients with bone metastases. |
| PubMedID- 21586099 | Interestingly, circulating levels of activin a in the serum of breast or prostate cancer patients with bone metastases are significantly higher than those of patients without bone metastases . |
| PubMedID- 21559805 | Objective: to evaluate the impact of biphosphonate administration on subsequent (153)samarium-ethylene-diamine-tetramethyl-phosphonate (edtmp) uptake in bone metastases of patients with castration-resistant prostate cancer. |
| PubMedID- 25320011 | Bone is the most frequent site of metastasis in prostate cancer and patients with bone metastases are deemed incurable. |
| PubMedID- 26182965 | The aim of this single-site, open-label clinical trial was to determine the biodistribution, pharmacokinetics, absorbed doses, and safety from 2 sequential weight-based administrations of (223)ra-dichloride in patients with bone metastases due to castration-refractory prostate cancer. |
| PubMedID- 22870908 | Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. |
| PubMedID- 20016889 | Conclusion: the addition of spect/ct resulted in a significant reduction of equivocal reports; a definitive diagnosis was given in the majority of the patients due to the improved diagnostic confidence compared to planar or spect imaging alone in prostate cancer patients with suspected bone metastases. |
| PubMedID- 21282368 | Serum ssao activity has also been shown to be higher in prostate cancer subjects with bone metastases than subjects without metastases (31). |
| PubMedID- 24604017 | Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases. |
| PubMedID- 22977313 | One remaining patient had prostate cancer with bone metastases and had received oral alendronate at the osteoporosis dose. |
| PubMedID- 22521546 | Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. |
| PubMedID- 22166808 | Bisphosphonates (bp) are used for the treatment of osteoporosis and bone metastases due to breast and prostate cancer. |
| PubMedID- 25573268 | Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases. |
| PubMedID- 23917308 | Background: due to concerns of fragility fracture, exercise is a perceived contraindication for prostate cancer patients with bone metastases. |
| PubMedID- 26030880 | Recent experimental findings have led to the development and use of the alpha- and beta-emitter 223ra to selectively target bone metastases in patients with castration-resistant prostate cancer . |
| PubMedID- 20515602 | Conclusion: administration of (153)sm to prostate cancer patients with painful bone metastases offered clinical relevant pain relief with tolerable hematological toxicity. |
| PubMedID- 21939550 | In the netherlands, a retrospective cost analysis study associated with bone metastases in patients with prostate cancer showed an average cost of 6,973 euros per patient to treat skeletal-related events . |
| PubMedID- 25811095 | More recently, the bone targeting, high let radionuclide (223)ra has been shown to not only have a palliative effect but also a survival prolonging effect in metastatic, castration-resistant prostate cancer with bone metastases. |